Floatz logo

METHYLAMINOLEVULINATE

Metastatic Ovarian Cancer

Institut du Cancer de Montpellier - Val d'AurelleSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Metastatic Ovarian Cancer cohort.

Asset / SponsorPhaseRating
TIL
Inge Marie Svane
Phase 2BB
Lipitor
Tampere University Hospital
Phase 3B
Young Til
National Cancer Institute (NCI)
Phase 2CCC
Nerofe
Immune System Key Ltd
Phase 1/2CCC
Relatlimab
Inge Marie Svane
Phase 1/2CCC
[18f]-azafol
University of Lausanne Hospitals
Phase 1CC
Erx-315
EtiraRx Australia Pty Ltd
Phase 1CC

Same molecule, other indications

METHYLAMINOLEVULINATE is also rated in:

Nodular Basal Cell Carcinoma of SkinDormant
B
Indicative ·
60 / 100
View asset →
GlioblastomaDormant
CCC
Indicative ·
52 / 100
View asset →
Rectal CancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →